Compounded Semaglutide vs Wegovy: What's Different

What each one is

Wegovy is a brand-name medicine that went through the FDA's drug approval process. Its prescribing information says the injection is indicated, along with a reduced-calorie diet and more physical activity, to reduce excess body weight and keep it off long term in adults and children 12 and older with obesity, and in adults with overweight plus at least one weight-related health condition. The label also lists approved uses for lowering the risk of major heart events in adults with heart disease, and for a type of liver disease called MASH. A once-daily Wegovy tablet is also approved.

Compounded semaglutide is prepared by a compounder, and compounded drugs are not FDA-approved. The FDA notes that compounding commonly happens in pharmacies, though it can also happen in other settings. It explains that compounding can serve a real purpose, such as a patient who is allergic to a dye in the approved product or who can't swallow a tablet. It also says compounded drugs should only be used in patients whose medical needs cannot be met by an FDA-approved drug.

The key point from the FDA: "Compounded drugs are not FDA-approved. This means that FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed."

Approval status side by side

The last row matters. The FDA notes that federal law does not require state-licensed pharmacies that are not outsourcing facilities to report adverse events to the agency, so problems with compounded versions are likely underreported.

Two kinds of compounders

Federal law sets up two main paths, and the quality rules differ.

• State-licensed pharmacies (section 503A). State boards of pharmacy handle most day-to-day oversight. The FDA does surveillance and for-cause inspections.
• Outsourcing facilities (section 503B). These register with the FDA, are inspected on a risk-based schedule, and must follow current good manufacturing practice (CGMP) requirements.

Either way, the product is still not FDA-approved.

Quality and dosing differences the FDA has flagged

The FDA keeps a page on its concerns with unapproved GLP-1 drugs used for weight loss. The issues it lists include:

• Dosing errors. The agency has received adverse-event reports, some requiring hospitalization, tied to dosing errors with compounded injectable semaglutide. Patients measured and gave themselves the wrong amount, and in some cases health care professionals miscalculated doses.
• Doses beyond the label. The FDA has also received reports from patients prescribed compounded semaglutide or tirzepatide in doses beyond what is in the approved label, including larger doses, more frequent doses or faster increases.
• Multi-dose vials. Compounded versions may come in vials that hold several doses. The FDA advises throwing a vial away 28 days after first use, even if medicine is left and even if the compounder's instructions say otherwise, and using a new, sterile needle and syringe every time.
• Shipping temperature. The agency has received complaints about compounded GLP-1 drugs arriving warm or with too little ice. It recommends not using any injectable GLP-1 drug that arrives warm or without proper refrigeration.
• Salt forms. Some compounders may use semaglutide sodium or semaglutide acetate. The FDA says these are different active ingredients from the one in the approved drugs, it has no information on whether they act the same way, and it is not aware of any lawful basis for using them in compounding.
• Fake labels. The FDA is aware of fraudulent compounded semaglutide and tirzepatide with false labels, including labels naming pharmacies that don't exist.

By contrast, Wegovy comes with FDA-approved prescribing information and patient instructions for its own pen and tablet. For the difference between those two forms, see our guide to the Wegovy pill vs the injection.

What the reports show

The FDA says that as of May 31, 2026 it had received 990 reports of adverse events associated with compounded semaglutide and more than 730 associated with compounded tirzepatide. The agency adds that it is not always possible to tell whether the drug caused the event, and that many of the reported events look like the known side effects of the approved versions.

Recalls are another signal worth knowing about. We cover how they work in our guide to compounded GLP-1 recalls.

Whatever your prescriber recommends, the day-to-day work is the same: meals, protein, sleep and movement. Olive is a health companion that checks in with you every day, looks at what you eat, and helps you build small habits that actually hold. It doesn't diagnose or treat anything, so medicine questions stay with your prescriber.

What the FDA's 503B proposal means

Outsourcing facilities generally can't compound from bulk ingredients unless the ingredient is on the FDA's "503B bulks list" or the drug is on the FDA's drug shortage list.

On April 30, 2026, the FDA announced it was proposing not to include semaglutide, tirzepatide and liraglutide on that list. It said it "did not identify a clinical need" for outsourcing facilities to compound these drugs from bulk substances. The notice was published in the Federal Register on May 1, 2026. The comment deadline was later extended to July 30, 2026, and the FDA says it will consider comments before making a final determination.

In plain terms, this is a proposal, not a final rule. If it is finalized as proposed, outsourcing facilities would generally not be able to compound these drugs from bulk ingredients while approved versions are available and not in shortage. Because rules here change, check the FDA's page or ask your pharmacist for the current status.

How the cost compares

Novo Nordisk posts self-pay prices for Wegovy on its NovoCare savings page. As of November 5, 2026, that page says self-pay pricing varies by form and dose, Wegovy pill prices start at $149 a month for self-paying patients, and some pen prices are introductory offers for new patients through December 31, 2026. It also says "Pricing to be updated after December 31, 2026." Check the NovoCare savings page for the price that fits your prescription, and ask your plan whether insurance covers it.

We don't list compounded prices. They vary by seller and change often, and the FDA warns that prices that "seem too good to be true" are a red flag for illegal online sellers.

Questions to ask your prescriber or pharmacy

• Is there an FDA-approved option that works for me, and if not, why?
• Who compounds this drug, and is it a state-licensed pharmacy or an FDA-registered outsourcing facility?
• Is the active ingredient semaglutide base, or a salt form?
• How exactly do I measure each dose, and who can I call with questions after it arrives?
• How will it be shipped and kept cold?
• How do I report a side effect or a problem with the product?

Not sure who can prescribe these medicines? See can a naturopath prescribe a GLP-1. Curious about very low doses? Our guide to microdosing GLP-1 evidence covers what's known.

Red flags when buying online

The FDA says to be wary of a seller that:

• claims its compounded drug is the same as an FDA-approved drug
• offers deep discounts or prices that seem too good to be true
• doesn't require a screening and prescription by a licensed doctor
• has no licensed doctor available after you receive the medicine
• sends medicine that looks different from what you were shown, or arrives damaged or without instructions

The FDA also warns against products labeled "for research purposes" or "not for human consumption." It calls these illegal and of unknown quality.

This guide is general information, not medical advice. Talk with your prescriber or pharmacist before starting, stopping or switching any medicine.

Support for the everyday part

Medicine choices belong with your prescriber. The habits around them are where daily support helps. Olive checks in with you every day and notices what's keeping your body stuck.

See how Olive works →